Antibodies, Monoclonal, Humanized

• 

  Subject Areas on Research

  • 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. 
  • 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). 
  • A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. 
  • A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. 
  • A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. 
  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. 
  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. 
  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 
  • A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. 
  • A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. 
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. 
  • A case report of mevalonate kinase deficiency in a 14-month-old female with fevers and lower extremity weakness. 
  • A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. 
  • A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A desensitization protocol for the mAb cetuximab. 
  • A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. 
  • A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. 
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. 
  • A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. 
  • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. 
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. 
  • A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 
  • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. 
  • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. 
  • A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). 
  • A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. 
  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. 
  • A prospective study of treatment patterns and 1-year outcome of Asian age-related macular degeneration and polypoidal choroidal vasculopathy. 
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. 
  • A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. 
  • Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab. 
  • Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. 
  • Adalimumab for the treatment of psoriasis. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Advances in Stroke 2017. 
  • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. 
  • Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. 
  • Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. 
  • Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 
  • Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. 
  • Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. 
  • Alemtuzumab induction in lung transplantation: time to move on? 
  • Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. 
  • Alemtuzumab. 
  • Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. 
  • Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. 
  • Alirocumab after acute coronary syndrome in patients with a history of heart failure. 
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. 
  • Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. 
  • Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. 
  • Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. 
  • Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. 
  • An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. 
  • Anti-Interleukin-6 Antibodies for Autoimmune Retinopathy with Macular Edema. 
  • Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. 
  • Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 
  • Anti-angiogenic therapy for high-grade glioma. 
  • Anti-angiogenic therapy in renal cell cancer. 
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. 
  • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. 
  • Antiangiogenic therapy for high-grade glioma. 
  • Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. 
  • Antibiotics and Immunotherapy: Too Much of Anything is Bad! 
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 
  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. 
  • Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. 
  • Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. 
  • Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. 
  • Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study. 
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. 
  • Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. 
  • Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. 
  • Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. 
  • Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. 
  • Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. 
  • Author reply: To PMID 24393349. 
  • Autoimmune pancerebellitis associated with pembrolizumab therapy. 
  • Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. 
  • Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications. 
  • Avastin: more questions than answers. . . 
  • Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. 
  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. 
  • BAFF is increased in renal transplant patients following treatment with alemtuzumab. 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. 
  • Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. 
  • Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients? 
  • Best practices for treatment of retinal vein occlusion. 
  • Bevacizumab for the treatment of high-grade glioma. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab and daily temozolomide for recurrent glioblastoma. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 
  • Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. 
  • Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. 
  • Bevacizumab for patients with metastatic renal cancer: an update. 
  • Bevacizumab for retinopathy of prematurity. 
  • Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Bevacizumab in colorectal cancer. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. 
  • Bevacizumab therapy for glioblastoma: a passionate discussion. 
  • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 
  • Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. 
  • Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. 
  • Bevacizumab: radiation combination produces restricted diffusion on brain MRI. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. 
  • Bronchiolitis. 
  • Burosumab for the Treatment of Tumor-Induced Osteomalacia. 
  • Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. 
  • CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. 
  • CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. 
  • CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. 
  • Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. 
  • Campath-1H in intestinal and multivisceral transplantation: preliminary data. 
  • Campath-1H in renal transplantation: The University of Wisconsin experience. 
  • Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. 
  • Campath-1H use in pediatric renal transplantation. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. 
  • Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. 
  • Cell signaling modifiers in prostate cancer. 
  • Cellular changes in eculizumab early responders with generalized myasthenia gravis. 
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. 
  • Certolizumab pegol. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. 
  • Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. 
  • Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. 
  • Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. 
  • Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. 
  • Colon cancer, version 3.2014. 
  • Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. 
  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Combined modality treatment for rectal cancer. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). 
  • Combining immunotherapy and radiotherapy for the STAR treatment. 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. 
  • Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). 
  • Compiling Observational Research During a Pandemic: A Necessary Bridge. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. 
  • Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. 
  • Consistent improvement with eculizumab across muscle groups in myasthenia gravis. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. 
  • Corneal penetration of topical and subconjunctival bevacizumab. 
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. 
  • Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. 
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. 
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 
  • Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 
  • Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. 
  • Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. 
  • Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. 
  • Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. 
  • Cutaneous Lupus Erythematosus: Progress and Challenges. 
  • D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. 
  • Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. 
  • Dawn of a New RAMPage. 
  • De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Denosumab for the treatment of osteoporosis. 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. 
  • Diagnosing acute myocardial infarction in patients with left bundle branch block. 
  • Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. 
  • Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. 
  • Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. 
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Discontinuation and management of direct-acting anticoagulants for emergency procedures. 
  • Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. 
  • Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. 
  • Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. 
  • Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. 
  • Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. 
  • Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. 
  • Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. 
  • Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. 
  • Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. 
  • Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. 
  • Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. 
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. 
  • Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. 
  • Eculizumab improves fatigue in refractory generalized myasthenia gravis. 
  • Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. 
  • Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? 
  • Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. 
  • Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. 
  • Effect of Alirocumab on Mortality After Acute Coronary Syndromes. 
  • Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. 
  • Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. 
  • Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. 
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 
  • Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. 
  • Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. 
  • Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. 
  • Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. 
  • Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. 
  • Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. 
  • Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. 
  • Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. 
  • Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. 
  • Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. 
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 
  • Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. 
  • Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. 
  • Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. 
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 
  • Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. 
  • Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. 
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. 
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. 
  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. 
  • Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 
  • Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. 
  • Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Emerging treatments for ulcerative colitis: a systematic review. 
  • Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 
  • Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. 
  • Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. 
  • Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. 
  • Evaluation of hypertension as a marker of bevacizumab efficacy. 
  • Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. 
  • Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus. 
  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 
  • Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. 
  • Experts on their own experiences: the rise of patient-reported outcomes in oncology drug trials. 
  • FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 
  • Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. 
  • Familial hypercholesterolemia: Detect, treat, and ask about family. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. 
  • Finding the right job for the tool: alemtuzumab and its role in renal transplantation. 
  • Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. 
  • First report of keratitis in familial cold autoinflammatory syndrome. 
  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. 
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. 
  • Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. 
  • From the editor: A run of success in treating atherosclerotic vascular disease. 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Gemtuzumab ozogamicin: is there room for salvage? 
  • Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). 
  • HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. 
  • HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. 
  • HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. 
  • Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 
  • Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors. 
  • Hidden biases in an observational study of bevacizumab beyond progression. 
  • High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. 
  • Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. 
  • Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. 
  • Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. 
  • How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation? 
  • Hsp90, an unlikely ally in the war on cancer. 
  • Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. 
  • IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. 
  • Idarucizumab for Dabigatran Reversal. 
  • Idarucizumab for dabigatran overdose. 
  • Idarucizumab since FDA approval: Use in the real-world. 
  • Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. 
  • Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark? 
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. 
  • Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. 
  • Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. 
  • Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. 
  • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. 
  • Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. 
  • Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. 
  • Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. 
  • Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. 
  • In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG. 
  • In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. 
  • Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. 
  • Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy. 
  • Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. 
  • Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. 
  • Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 
  • Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. 
  • Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. 
  • Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). 
  • Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. 
  • International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. 
  • Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. 
  • Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. 
  • Intravenous Migraine Treatment in Children and Adolescents. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. 
  • Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. 
  • Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. 
  • Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. 
  • Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas. 
  • Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. 
  • Is This a 737 Max Moment for Brolucizumab? 
  • Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. 
  • Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. 
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. 
  • Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. 
  • Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. 
  • Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. 
  • Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. 
  • Life threatening liver disease during treatment with monoclonal antibodies. 
  • Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. 
  • Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. 
  • Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. 
  • Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. 
  • Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. 
  • Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. 
  • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. 
  • Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. 
  • Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. 
  • Making genuine progress against metastatic breast cancer. 
  • Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. 
  • Management of bronchiolitis in infants and children. 
  • Management of hearing in pediatric NF2. 
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. 
  • Marked clinical and jitter improvement after eculizumab in refractory myasthenia. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. 
  • Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. 
  • Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. 
  • N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 
  • Neoadjuvant chemotherapy in breast cancer: what questions remain? 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma? 
  • Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. 
  • New and emerging therapies for bone metastases in genitourinary cancers. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. 
  • Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. 
  • Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. 
  • Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. 
  • Novel oral anticoagulants and reversal agents: Considerations for clinical development. 
  • Novel--and "neu"--therapeutic possibilities for heart failure. 
  • Obesity following kidney transplantation and steroid avoidance immunosuppression. 
  • Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. 
  • Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. 
  • Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. 
  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. 
  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. 
  • PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. 
  • PET concerns in bevacizumab treatment. 
  • PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. 
  • Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. 
  • Pediatric neuro-Behçet's disease responsive to adalimumab. 
  • Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. 
  • Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. 
  • Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. 
  • Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. 
  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pexelizumab and the APEX AMI trial. 
  • Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. 
  • Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. 
  • Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. 
  • Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). 
  • Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. 
  • Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. 
  • Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. 
  • Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. 
  • Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. 
  • Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. 
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). 
  • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 
  • Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. 
  • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. 
  • Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. 
  • Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. 
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. 
  • Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. 
  • Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. 
  • Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. 
  • Preventing Cognitive Decline. 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Profile of adalimumab and its potential in the treatment of uveitis. 
  • Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). 
  • Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. 
  • Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. 
  • Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. 
  • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. 
  • Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. 
  • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. 
  • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Pseudoprogression of Metastatic Melanoma to the Orbit With Pembrolizumab. 
  • QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. 
  • Quality of life in ICON7: need for patients' perspectives. 
  • RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. 
  • RECONSTITUTION OF THE ELLIPSOID ZONE WITH TOCILIZUMAB IN AUTOIMMUNE RETINOPATHY. 
  • Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. 
  • Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. 
  • Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 
  • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. 
  • Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. 
  • Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). 
  • Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Ranibizumab and bevacizumab for neovascular age-related macular degeneration. 
  • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. 
  • Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. 
  • Ranibizumab for neovascular age-related macular degeneration. 
  • Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. 
  • Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS). 
  • Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. 
  • Reading speed improvements in retinal vein occlusion after ranibizumab treatment. 
  • Recurrent malignant gliomas. 
  • Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. 
  • Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab. 
  • Refractory myasthenia gravis exacerbation triggered By pembrolizumab. 
  • Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. 
  • Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. 
  • Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? 
  • Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. 
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 
  • Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience With Canakinumab. 
  • Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. 
  • Reperfusion edema after lung transplantation: effect of daclizumab. 
  • Reply to Comment on: Is this a 737 Max Moment for Brolucizumab? 
  • Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. 
  • Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing. 
  • Reply. 
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. 
  • Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine. 
  • Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. 
  • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. 
  • Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. 
  • Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). 
  • Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. 
  • Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. 
  • Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD. 
  • Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. 
  • Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study. 
  • Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. 
  • Reversal agents for non-vitamin K antagonist oral anticoagulants. 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. 
  • Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. 
  • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. 
  • ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. 
  • Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. 
  • Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. 
  • Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. 
  • Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. 
  • Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. 
  • Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. 
  • Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. 
  • Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. 
  • Secukinumab (AIN-457) for the treatment of Psoriasis. 
  • Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. 
  • Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. 
  • Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. 
  • Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. 
  • Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. 
  • Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report. 
  • Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. 
  • Spondyloarthritis in a patient with unilateral buttock pain and history of Crohn disease. 
  • Stem cell transplantation for multiple myeloma. 
  • Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes. 
  • Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. 
  • Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. 
  • Subcutaneous efalizumab is not effective in the treatment of alopecia areata. 
  • Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. 
  • Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. 
  • Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. 
  • Survival after brain metastases from breast cancer in the trastuzumab era. 
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. 
  • Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. 
  • Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. 
  • Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. 
  • Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. 
  • T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. 
  • T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Targeted inhibition of VEGF receptor 2: an update on ramucirumab. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy in rectal cancer. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer. 
  • Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. 
  • Targeting the Effect of VEGF in Diabetic Macular Edema. 
  • Targeting the future in head and neck cancer. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. 
  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. 
  • The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The calm after the cytokine storm: lessons from the TGN1412 trial. 
  • The cam-path forward. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. 
  • The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. 
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants. 
  • The interleukin-2 receptor α chain (CD25) plays an important role in regulating monocyte-derived CD40 expression during anti-porcine cellular responses. 
  • The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. 
  • The paradoxical effect of bevacizumab in the therapy of malignant gliomas. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
  • Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. 
  • Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. 
  • Therapy of inflammatory bowel disease: what to expect in the next decade. 
  • Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. 
  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. 
  • Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. 
  • Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases. 
  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Topical bevacizumab therapy for corneal neovascularization. 
  • Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. 
  • Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. 
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 
  • Trastuzumab emtansine for HER2-positive advanced breast cancer. 
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. 
  • Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. 
  • Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. 
  • Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? 
  • Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. 
  • Treatment of age-related macular degeneration. 
  • Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. 
  • Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. 
  • Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. 
  • Trends in age-related macular degeneration management in Singapore. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. 
  • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. 
  • Updates on Merkel Cell Carcinoma. 
  • Use of trastuzumab in the treatment of metastatic endometrial cancer. 
  • Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. 
  • Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Esclamado, Ramon Mitra, Professor Emeritus of Head and Neck Surgery and Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Fekrat, Sharon, Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society